Enabling allogeneic therapies: CIRM-funded strategies for immune tolerance and immune evasion. (25th June 2020)

• Record Type: Journal Article
• Authors: Kadyk, Lisa C.; Okamura, Ross M.; Talib, Sohel
• Is Part Of: Stem cells translational medicine. Volume 9:Number 9(2020)
• Page Start: 959
• Page End: 964
• Publication Date: 2020-06-25
• Subjects: immunosuppression -- cell transplantation -- donor-specific tolerance -- hematopoietic chimerism -- immune reconstitution -- T cell -- tissue engineering; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.20-0079
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: A major goal for the field of regenerative medicine is to enable the safe and durable engraftment of allogeneic tissues and organs. In contrast to autologous therapies, allogeneic therapies can be produced for many patients, thus reducing costs and increasing availability. However, the need to overcome strong immune system barriers to engraftment poses a significant biological challenge to widespread adoption of allogeneic therapies. While the use of powerful immunosuppressant drugs has enabled the engraftment of lifesaving organ transplants, these drugs have serious side effects and often the organ is eventually rejected by the recipient immune system. Two conceptually different strategies have emerged to enable durable engraftment of allogeneic therapies in the absence of immune suppression. One strategy is to induce immune tolerance of the transplant, either by creating "mixed chimerism" in the hematopoietic system, or by retraining the immune system using modified thymic epithelial cells. The second strategy is to evade the immune system altogether, either by engineering the donor tissue to be "invisible" to the immune system, or by sequestering the donor tissue in an immune impermeable barrier. We give examples of research funded by the California Institute for Regenerative Medicine (CIRM) in each of these areas, ranging from early discovery-stage work through clinical trials. The advancements that are being made in this area hold promise that many more patients will be able to benefit from regenerative medicine therapies in the future. :